| Title | Nicotinamide drives T cell activation in the mammary tumor microenvironment. |
| Publication Type | Journal Article |
| Year of Publication | 2022 |
| Authors | Hu Y, Bloy N, Elemento O, Buqué A |
| Journal | J Transl Med |
| Volume | 20 |
| Issue | 1 |
| Pagination | 251 |
| Date Published | 2022 Jun 03 |
| ISSN | 1479-5876 |
| Keywords | Animals, CD8-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Mice, Niacinamide, Programmed Cell Death 1 Receptor, Tumor Microenvironment |
| Abstract | Nicotinamide (NAM, a variant of vitamin B) has recently been shown to accelerate the activation of human CD4 and CD8 T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also express multiple markers of late-stage activation. Taken together, these findings lend additional support to the notion that the antineoplastic effects of NAM involve at least some degree of restored cancer immunosurveillance. |
| DOI | 10.1186/s12967-022-03454-z |
| Alternate Journal | J Transl Med |
| PubMed ID | 35659314 |
| PubMed Central ID | PMC9164530 |